MedTrace Logo

Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder

NCT00203528 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2007-03-19

No results posted yet for this study

Summary

The primary objective is to evaluate the safety and efficacy of divalproex extended release (ER) compared to risperidone in the treatment of bipolar disorder with comorbid substance use disorder

Conditions

Interventions

DRUG

divalproex sodium ER

DRUG

risperidone

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Tuscaloosa Research & Education Advancement Corporation

    lead OTHER

Principal Investigators

  • Lori L Davis, MD · Tuscaloosa Veterans Affairs Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203528 on ClinicalTrials.gov